Claud Grigg

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Diego Chowell, Luc G.T. Morris, Claud Grigg et al. · Science · 2017 · 1.1K citations

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

Catherine A. Shu, Justin F. Gainor, Mark M. Awad et al. · The Lancet Oncology · 2020 · 621 citations

Oncology, Metronomic Therapy, Pathology +6

Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC).

Catherine A. Shu, Claud Grigg, Codruța Chiuzan et al. · Journal of Clinical Oncology · 2018 · 46 citations

Surgical Oncology, Pd-l1- Pts, Medicine +14

Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade.

Claud Grigg, Brian D. Reuland, Adrian G. Sacher et al. · Journal of Clinical Oncology · 2017 · 42 citations

Cancer Management, Immunology, Objective Response Rates +17

Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions

Earle F. Burgess, Chad Livasy, Aaron Hartman et al. · Urologic Oncology Seminars and Original Investigations · 2019 · 37 citations

Urology, High Pd-l1 Expression, Genitourinary Cancer +5